Navigation Links
Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Date:4/26/2011

SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has received a $7 million milestone payment for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier ("Servier") based on an ex-US collaboration agreement signed in April of 2009.  Over the past two years Servier has engaged in several exploratory Phase I/II trials in solid tumors and hematologic malignancies.  Servier is now focused on its Phase II programs to enable the registration pathway for PCI-24781 / S 78454.

"Five phase I and I/II trials are ongoing in Europe in lymphomas and solid tumors. The first results are very encouraging in terms of clinical activity and safety profile and we plan to start soon new combination trials," said Stephane Depil MD, PhD, Director of Oncology Research and Development Unit at Servier.

"Servier is delighted to work with Pharmacyclics under this partnership," said Emmanuel Canet MD, PhD, Servier's President, Research and Development. "The molecule PCI-24781 / S 78454 has performed well in a variety of early stage trials and exceeds our expectations. We plan to further expand the clinical development of PCI-27481 / S 78454."

Mr. Robert Duggan, Pharmacyclics CEO & Chairman, added, "we are very pleased with the progress of PCI-24781 / S 78454 and the alliance with Servier. We are looking forward to work closely with our partner to advance this molecule to the market."

About HDAC Inhibitor, PCI-24781 / S 78454 is an orally-bioavailable histone deacetylase (HDAC) inhibitor that is currently in multiple clinical trials in the United States and the European Union.  The US trials include a Phase II trial in patients with recurrent lymphomas and a Phase I/II trial in sarcoma patients (in combination with doxorubicin, an anti tumor agent). Hi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Secures $5.0 Million in Debt Financing
4. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
8. Pharmacyclics Announces Subscription Price for Rights Offering
9. Pharmacyclics, Inc. Rights Offering Oversubscribed
10. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
11. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Horsham, PA (PRWEB) April 17, 2015 ... Tech), a leader in regulatory data management, preparation, and ... announced today the availability of a new Lot Distribution ... that are required to remain compliant with the FDA’s ... Used by the FDA to monitor the volume and ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
(Date:4/16/2015)... 2015 Spirax Sarco, the leader ... their newly designed, state-of-the-art website in the first ... effectively promotes the Spirax Sarco brand, company capabilities, ... that a site visitor might be looking for ... industries serviced, the latest company news, careers, and ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6Spirax Sarco website has a new look 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2
... Ill., April 9 Baxter Healthcare Corporation,today ... VitalShield,protective coating, the first needleless intravenous (IV) ... available for hospitals in the,United States and ... to kill on,average 99.9 percent or more ...
... April 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... its U.K. combination REOLYSIN(R) and carboplatin/paclitaxel,trial. Dr. ... Research, London,and the principal investigator for the ... Annual Conference of the British Society for ...
... Contest, PARSIPPANY, N.J., April 9, 2008 If ... Ferring Pharmaceuticals, fertility,products, you can win a $10,000 education ... prizes will also be awarded. To be,eligible, all you ... topic is: If I,Knew Then What I Know Now, ...
Cached Biology Technology:Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial 3Win a $10,000 Education Fund for Your Miracle Child 2Win a $10,000 Education Fund for Your Miracle Child 3
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... diseases shall be diagnosed earlier and treated more successfully ... European countries*, coordinated by the Max Delbrck Center for ... the past four-and-a half years to create a three-dimensional ... on the development and diseases of the kidney. The ...
... of a termite entombed for 100 million years in an ... "mutualism" ever discovered between an animal and microorganism, and also ... the most successful, although frequently despised insect groups in the ... Oregon State University researcher and international expert on life forms ...
... statistical analyses and advanced computer simulations, researchers ... of human population structure around the world. ... the history of human evolution, the predominant ... the relationships among populations. "Studying genomic ...
Cached Biology News:3-D kidney atlas created for researchers and physicians 2Diuscovery in amber reveals ancient biology of termites 2Diuscovery in amber reveals ancient biology of termites 3Researchers gain genome-wide insights into patterns of the world's human population structures 2Researchers gain genome-wide insights into patterns of the world's human population structures 3
... EPS 301 Power Supply, 1. 300 ... voltage or constant current modes.Single-unit increments ... and reproducibility.Suitable for submarine, mini vertical, ... well as semidry and mini tank ...
... EPS 1001 Power Supply, 1. 1000 ... voltage, constant current, and constant power ... for precision and reproducibility.Stores and recalls ... flatbed gels on Multiphor II ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: